- Home
- ERNA vs QNRX Comparison
ERNA vs QNRX Comparison
Compare ERNA & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ERNA | QNRX |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 10.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ERNA | QNRX |
|---|---|---|
| Price | $1.21 | $13.99 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 41.4K | ★ 93.9K |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.09 | $5.01 |
| 52 Week High | $14.40 | $41.80 |
Technical Indicators
Market Signals| Indicator | ERNA | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.27 | 49.38 |
| Support Level | $1.22 | $12.92 |
| Resistance Level | $1.31 | $14.46 |
| Average True Range (ATR) | 0.10 | 1.65 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 12.90 | 73.66 |
Price Performance
Historical ComparisonAbout ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.